Pharmacological strategies and micrometastasis: What is known? What must be done?

Minerva Medica

Volumn 101, Issue 3, 2010, Pages 163-178

  Perret, G Y ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Antineoplastic agents; Neoplasm metastasis; Neoplasm, residual

Indexed keywords

AMENTOFLAVONE; AMG 487; ANGIOGENESIS INHIBITOR; ANTIMETASTATIC AGENT; ANTITHROMBOCYTIC AGENT; C 90; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOOXYGENASE 2 INHIBITOR; DNA METHYLTRANSFERASE INHIBITOR; FINGOLIMOD; FUMAGILLOL CHLOROACETYLCARBAMATE; GLUCARO 1,5 LACTAM; HEPARIN DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; MACROLIDE; METHYLUMBELLIFERONE; NITRIC OXIDE DONOR; PARTHENOLIDE; PROSTAGLANDIN INHIBITOR; RUTHENIUM COMPLEX; THERMOZYMOCIDIN; UMBELLIFERONE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 3;

CANCER CELL; CELL ADHESION; CELL INVASION; CELL MOTILITY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; HUMAN; LYMPHANGIOGENESIS; METASTASIS INHIBITION; MICROMETASTASIS; MINIMAL RESIDUAL DISEASE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SUPPRESSOR GENE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL MOVEMENT; DRUG DISCOVERY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77957687996     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (175)

1. Boyd D. Invasion and metastasis. Cancer Metast Rev 1996;15:77-89.
2. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 2009;69:7135-9.
3. Noren NK, Liu BP, Burridge K, Kreft B. p120 catenin regulates the actin cytoskeleton via Rho family GTPases. J Cell Biol 2000;150:567-80. (Pubitemid 30641401)
4. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008;68:3645-54.
5. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 2000;148:779-90.
6. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005;17:548-58
7. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009;15:195-206.
8. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008;14:79-89.
9. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
10. Hofmann C, Obermeier F, Artinger M, Hausmann M, Falk W, Schoelmerich J et al. Cell-cell contacts prevent anoikis in primary human colonic epithelial cells. Gastroenterology 2007;132:587-600.
11. Palumbo JS, Talmage KE, Massari JV, Lajeunesse CM, Flick MJ, Kombrinck KW et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105:178-85
12. Alonsoescolano D, Medina C, Cieslik K, Radomski A, Jurasz P, Santosmartinez MJ et al. Protein kinase C delta mediates platelet-induced breast cancer cell invasion. J Pharmacol Exp Ther 2006;318:373-80.
13. Pinedo HM, Verheul HMW, Damato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998;352:1775-7.
14. Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest 2004;114:1691-3. (Pubitemid 40385522)
15. Panes J, Perry M, Granger DN. Leukocyte endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999;126:537-50.
16. Zen K, Parkos CA. Neutrophil migration across endothelium: transcellular or paracellular? Blood 2005;106:394-5.
17. Lessner SM, Galis ZS. Matrix metalloproteinases and vascular endothelium-mononuclear cell close encounters. Trends Cardiovasc Med 2004;14:105-11.
18. Leroydudal J, Demeilliers C, Gallet O, Pauthe E, Dutoit S, Agniel M et al. Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alpha v integrins and the participation of MMP2. Int J Cancer 2005;114:531-43.
19. Lafferriere J, Houle F, Huot J. Adhesion of HT-29 colon carcinoma cells to endothelial cells requires sequential events involving E-selectin and integrin beta 4. Clin. Exp. Metastasis 2004;21:257-64.
20. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004;95:377-84.
21. Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S et al. Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci USA 2004;101:8132-7.
22. Rollin S, Lemieux C, Maliba R, Favier J, Villeneuve LR, Allen BG et al. VEGF-mediated endothelial P-selectin translocation: role of VEGF receptors and endogenous PAF synthesis. Blood 2004;103:3789-97.
23. Stcroix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
24. Ruoslahti E. Specialization of tumour vasculature. Nature Rev Cancer 2002;2:83-90.
25. Li JL, Harris AL. The potential of new tumor endothelium-specific markers for the development of antivascular therapy. Cancer Cell 2007;11:478-81.
26. Fidler IJ. Timeline - The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Rev. Cancer 2003;3:453-8.
27. Kaplan RN, Rafii S, Lyden D. Preparing the "Soil": The premetastatic niche. Cancer Res. 2006;66:11089-93.
28. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E et al. A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype. J. Nat. Cancer Inst. 2006;98:316-25.
29. Aguirreghiso JA. The problem of cancer dormancy - Understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle 2006;5:1740-3.
30. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion - Migrating cancer stem cells - an integrated concept of malignant tumour progression. Nature Rev Cancer 2005;5:744-9.
31. Rinkerschaeffer CW, O'Keefe JP, Welch DR, Theodorescu D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 2006;12:3882-9. (Pubitemid 44078070)
32. Ruan K, Song G, Ouyang GL. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009;107:1053-62.
33. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur. J. Cancer 2000;36:1649-60.
34. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nature Reviews Cancer 2009;9:285-93.
35. McGowan PM, Kirstein JM, Chambers AF. Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncology 2009;5:1083-98.
36. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F et al. Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer Cell 2009;15:220-31.
37. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
38. Friedl P, Wolf K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nature Rev. Cancer 2003;3:362-74.
39. Decaestecker C, Debeir O, Vanham P, Kiss R. Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med. Res. Rev. 2007;27:149-76
40. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007;9:893-904.
41. Gatesman A, Walker VG, Baisden JM, Weed SA, Flynn DC. Protein kinase C alpha activates c-Src and induces podosome formation via AFAP-110. Mol Cell Biol 2004;24:7578-97.
42. Burridge K, Doughman R. Front and back by Rho and Rac Nat Cell Biol 2006;8:781-2.
43. Schwartz MA, Horwitz AR. Integrating adhesion, protrusion, and contraction during cell migration. Cell 2006;125:1223-5.
44. Horwitz AR, Parsons JT. Cell biology - Cell migration - Movin' on. Science 1999;286:1102-3
45. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002;2:161-74. (Pubitemid 37328786)
46. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997;72:1-22.
47. Boccaccio C, Comoglio PM. A functional role for hemostasis in early cancer development. Cancer Res 2005;65:8579-82.
48. Boyd DD, Nakajima M. Involvement of heparanase in tumor metastases: A new target in cancer therapy? J Nat Cancer Inst 2004;96:1194-5.
49. Sheetz MP, Felsenfeld DP, Galbraith CG. Cell migration: Regulation of force on extracellular-matrix-integrin complexes. Trends Cell Biol 1998;8.51-4.
50. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer. A new therapeutic opportunity. Nature Rev Cancer 2005;5:505-15
51. Aznar S, Fernandez-Valeron P, Espina C, Lacal JC. Rho GTPases: potential candidates for anticancer therapy. Cancer Letters 2004;206:181-91.
52. Nishimura Y. Gem-diamine 1-N-iminosugars, a new family of glycosidase inhibitors: Synthesis and biological activity. Heterocycles 2006;67:461-88.
53. Miao HQ, Liu H, Navarro E, Kussie P, Zhu ZP. Development of heparanase inhibitors for anti-cancer therapy. Curr. Med. Chem. 2006;13:2101-11.
54. Saiki I, Yoneda J, Kobayashi H, Igarashi Y, Komazawa H, Ishizaki Y et al. Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs. Jpn J Cancer Res 1993;84:326-35.
55. Kim WH, Nomizu M, Song SY, Tanaka K, Kuratomi Y, Kleinman HK et al. Laminin-alpha1-chain sequence Leu-Gln-Val-Gln-Leu-Ser-Ile-Arg (LQVQLSIR) enhances murine melanoma cell metastases. Int J Cancer 1998;77:632-9.
56. Stadel JM, Nichols AJ, Bertolini DR, Samanen JM. Therapeutic potential of integrin antagonists. In: Cheresh DA, Mecham RP, editors. Integrins. San Diego: Academic Press Inc; 1994. p. 237-71.
57. Shannon KE, Keene JL, Settle SL, Duffin TD, Nickols MA, Westlin M et al. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin. Exp. Metastasis 2004;21:129-38.
58. Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: A surge of new developments increasingly target tumor and stroma. Drug Resistance Updates 2007;10:182-93.
59. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998;94:353-62.
60. Guruvayoorappan C, Kuttan G. Effect of amentoflavone on the inhibition of pulmonary metastasis induced by B16F-10 melanoma cells in C57BL/6 mice. Integrative Cancer Therapies 2007;6:185-97.
61. Kishida Y, Yoshikawa H, Myoui A. Parthenolide, a natural inhibitor of nuclear factor-kappa B, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 2007;13:59-67. (Pubitemid 46121853)
62. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005;437:497-504
63. Criscuoli ML, Nguyen M, Eliceiri BP. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 2005;105:1508-14.
64. Katz E, Streuli CH. The extracellular matrix as an adhesion checkpoint for mammary epithelial function. Int J Biochem Cell Biol 2007;39:715-26.
65. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
66. Liotta LA, Kohn E. Anoikis - Cancer and the homeless cell. Nature 2004;430:973-4.
67. Liu Z, Li H, Wu X, Yoo BH, Yan SR, Stadnyk AW et al. Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells. Oncogene 2006;25:7680-90.
68. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin Iib-Iiia, fibronectin and von-willebrand-factor on tumor adhesion in-vitro and metastasis in-vivo. Thrombosis and Haemostasis 1995;74:282-90.
69. Janowskawieczorek A, Wysoczynski M, Kijowski J, Marquezcurtis L, Machalinski B, Ratajczak J et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int JCancer 2005;113:752-60.
70. Meromsky L, Lotan R, Raz A. Implications of endogenous tumor cell surface lectins as mediators of cellular interactions and lung colonization. Cancer Res 1986;46:5270-5.
71. Glinsky GV, Price JE, Glinsky W, Mossine W, Kiriakova G, Metcalf JB. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Research 1996;56:5319-24.
72. Gomes N, Vassy J, Lebos C, Arbeille B, Legrand C, Fauvellafeve F. Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole bloodand under flow conditions: Effects of alpha(V)beta(3) and alpha(II)beta(3) antagonists. Clin. Exp. Metastasis 2004;21:553-61.
73. Finzel AH, Reininger AJ, Bode PA, Wurzinger LJ. ICAM-1 supports adhesion of human small-cell lung carcinoma to endothelial cells. Clin Exp Metastasis 2004;21:185-9.
74. Allport JR, Weissleder R. Murine lewis lung carcinoma-derived endothelium expresses markers of endothelial activation and requires tumor-specific extracellular matrix in vitro. Neoplasia 2003;5:205-17.
75. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2003;4:393-403 (Pubitemid 37491100)
76. Ruoslahti E, Duza T, Zhang L. Vascular homing peptides with cell-penetrating properties. Curr Pharm Design 2005;11:3655-60.
77. Shirota K, Kato Y, Irimura T, Kondo H, Sugiyama Y. Anti-metastatic effect of the sialyl Lewis-X analog GSC-150 on the human colon carcinoma derived cell line KM12-HX in the mouse. Biol Pharmaceut Bull 2001;24:316-9.
78. Park K, Lee SK, Son DH, Park SA, Kim K, Chang HW et al. The attenuation of experimental lung metastasis by a bile acid acylated-heparin derivative. Biomaterials 2007;28:2667-76.
79. Borsig L, Wang LC, Cavalcante MCM, Cardilo-Reis L, Ferreira PL, Mourao PAS et al. Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber - Effect on tumor metastasis and neutrophil recruitment. Journal of Biol Chem 2007;282:14984-91.
80. Ishikawa D, Kikkawa H, Ogino K, Hirabayashi Y, Oku N, Taki T. GD1 alpha-replica peptides functionally mimic GD1 alpha, an adhesion molecule of metastatic tumor cells, and suppress the tumor metastasis. FEBS Lett. 1998;441:20-4.
81. Itano N, Sawai T, Miyaishi O, Kimata K. Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cell. Cancer Res 1999;59:2499-504. (Pubitemid 29242303)
82. Yoshihara S, Kon A, Kudo D, Nakazawa H, Kakizaki I, Sasaki M et al. A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. Febs Letters 2005;579:2722-6.
83. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-7.
84. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995;1:27-31.
85. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002;29:15-8.
86. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993;53:2566-70.
87. Teicher BA. Angiogenesis and cancer metastases: Therapeutic approaches. Critical reviews in oncology/hematology 1995;20:9-39.
88. Fulton AM, Ma XR, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res. 2006;66:9794-7.
89. Yang L, Huang YH, Porta R, Yanagisawa K, Gonzalez A, Segi E et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res. 2006;66:9665-72.
90. Kobayashi H, Gonda T, Uetake H, Higuchi T, Enomoto M, Sugihara K. Jte-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: A vascular cast model study. Int J Cancer 2004;112:920-6.
91. Backhus LM, Sievers E, Lin GY, Castanos R, Bart RD, Starnes VA et al. Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer. J Thorac Cardiovasc Surg 2006;132:297-303
92. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Research 1992;52:5575-89.
93. Nie DT, Honn KV. Eicosanoid regulation of angiogenesis in tumors. Semin Thromb Hemost 2004;30:119-25.
94. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Setde SL, Woerner BM et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
95. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-25.
96. Bhargava S, Hotz B, Hines O, Reber H, Buhr H, Hotz H. Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. J Gastrointest Surg 2007;11:171-8.
97. Hagiwara A, Sakakura C, Shirasu M, Togawa T, Sonoyama Y, Fujiyama J et al. Intraperitoneal injection of dextran sulfate as an anti-adherent drug for the prevention of peritoneal metastasis of cancer shows low toxicity in animals. Antican Drugs 2000;11:393-9.
98. Bagheriyarmand R, Kourbali Y, Rath AM, Vassy R, Martin A, Jozefonvicz J et al. Carboxymethyl benzylamide dextran blocks angiogenesis of MDA-MB435 breast carcinoma xenografted in fat pad and its lung metastases in nude mice. Cancer Res 1999;59:507-10.
99. Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thrombos Hemost 2007;33:557-62.
100. Chen JL, Hong J, Lu JL, Chen MX, Chen WX, Zhu JS et al. Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma. World J Gastroenterol 2007;13:457-61.
101. Ono K, Ishihara M, Ishikawa K, Ozeki Y, Deguchi H, Sato M et al. Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung. Br J Cancer 2002;86:1803-12.
102. Hammakourbali Y, Vassy R, Starzec A, Lemeuthmetzinger V, Oudar O, Bagheriyarmand R et al. Vascular endothelial growth factor 165 (VEGFG65)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165). KDR complexes. J Biol Chem 2001;276:39748-54. (Pubitemid 33658165)
103. Bittoun P, Bagheri-yarmand R, Chaubet F, Crépin M, Jozefonvicz J, Fermandjian S. Effects of the binding of a dextran derivative on fibroblast growth factor 2: secondary structure and receptor-binding studies. Biochem Pharmacol 1999;57:1399-406.
104. Joyce JA, Freeman C, Meyermorse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 2005;24:4037-51.
105. Pan Q, Kleer CG, Vangolen KL, Irani J, Bottema KM, Bias C et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62:4854-9.
106. Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD, Teknos TN. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 2007;6:1039-45. (Pubitemid 46554574)
107. Fujii H, Nishikawa N, Komazawa H, Suzuki M, Kojima M, Itoh I et al. A new pseudo-peptide of Arg-Gly-Asp (RGD) with inhibitory effect on tumor metastasis and enzymatic degradation of extracellular matrix. Clin Exper Metast 1998;16:94-104.
108. Komazawa H, Saiki I, Aoki M, Kitaguchi H, Satoh H, Kojima M et al. Synthetic Arg-Gly-Asp-Ser analogs of the cell recognition site of fibronectin that retain antimetastatic and anti-cell adhesive properties. Biol Pharmaceut Bull 1993;16:997-1003.
109. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S et al. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Research 2000;60:309-20.
110. Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006;94:1621-6.
111. Khalili P, Arakelian A, Chen GP, Plunkett ML, Beck I, Parry GC et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Molecular Cancer Therapeutics 2006;5:2271-80.
112. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003;63:8890-8.
113. Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C et al. Angiogenesis as a target for tumor treatment. Oncology 1997;54:177-84.
114. Yatsunami J, Tsuruta N, Hara N, Hayashi S. Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett 1998;131:137-43. (Pubitemid 28479781)
115. Yatsunami J, Tsuruta N, Fukuno Y, Kawashima M, Taniguchi S, Hayashi S. Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells. Clin Exp Metastasis 1999;17:119-24.
116. Guba M, Vonbreitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Med 2002;8:128-35.
117. McCarty MF, Bielenberg D, Donawho C, Bucana CD, Fidler IJ. Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis 2002;19:609-15.
118. Ozawa S, Shinohara H, Kanayama H, Bruns CJ, Bucana CD, Ellis LM et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 2001;3:154-64.
119. Minagawa N, Nakayama Y, Inoue Y, Onitsuka K, Katsuki T, Tsurudome Y et al. 4-[3,5-bis(Trimethylsilyl) benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor. Oncol Res 2004;14:407-14.
120. Jones MK, Tsugawa K, Tarnawski AS, Baatar D. Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochem Biophys Res Commun 2004;318:520-8.
121. Pipilisynetos E, Papageorgiou A, Sakkoula E, Sotiropoulou G, Fotsis T, Karakiulakis G et al. Inhibition of Angiogenesis, Tumor-Growth and Metastasis by the No-Releasing Vasodilators, Isosorbide Mononitrate and Dinitrate. British Journal of Pharmacology 1995;116:1829-34.
122. Lala PK, Orucevic A. Role of nitric oxide in tumor progression: Lessons from experimental tumors. Cancer Metastasis Rev 1998;17:91-106 (Pubitemid 28194648)
123. Mortensen K, Christensen IJ, Nielsen HJ, Hansen U, Larsson LI. High expression of endothelial cell nitric oxide synthase in peritumoral microvessels predicts increased disease-free survival in colorectal cancer. Cancer Letters 2004;216:109-14.
124. Jain RK, Fenton BT. Intratumoral lymphatic vessels: A case of mistaken identity or malfunction? J Nat Cancer Inst 2002;94:417-21.
125. Clarijs R, Ruiter DJ, Dewaal RMW. Lymphangiogenesis in malignant tumours: does it occur? J Pathol 2001;193:143-6.
126. Padera TP, Kadambi A, Ditomaso E, Carreira CM, Brown EB, Boucher Y et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-6.
127. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007;8:464-78.
128. Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exper Med 2007;204:1431-40.
129. Williams CS, Leek RD, Robson AM, Banerji S, Prevo R, Harris AL et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 2003;200:195-206.
130. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylaherttuala S, Jaattela M et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786-90.
131. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer 2006;94:1355-60.
132. He YL, Kozaki KI, Karpanen T, Koshikawa K, Ylaherttuala S, Takahashi T et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Nat Cancer Inst 2002;94:819-25.
133. Kuramitsu Y, Hamada J, Tsuruoka T, Morikawa K, Kobayashi H, Hosokawa M. A new anti-metastatic drug, ND-2001, inhibits lung metastases in rat hepatoma cells by suppressing haptotaxis of tumor cells toward laminin. Anticancer Drugs 1998;9:88-92. (Pubitemid 28088184)
134. Yan L, Anderson GM, Dewitte M, Nakada MT. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 2006;42:793-802
135. Castagna A, Biswas P, Beretta A, Lazzarin A. The appealing story of HIV entry inhibitors - From discovery of biological mechanisms to drug development. Drugs 2005;65:879-904.
136. Takenaga M, Tamamura H, Hiramatsu K, Nakamura N, Yamaguchi Y, Kitagawa A et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochemical and Biophysical Research Communications 2004;320:226-32.
137. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. Febs Letters 2003;550:79-83.
138. Kawada K, Sonoshita M, Sakashita H, Takabayashi A, Yamaoka Y, Manabe T et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004;64:4010-7.
139. Walser TC, Rifat S, Ma XR, Kundu N, Ward C, Goloubeva O et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 2006;66:7701-7.
140. Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Nat Cancer Inst 2003;95:1747-57.
141. Chang HC, Cho CY, Hung WC. Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation. Cancer Res. 2006;66:8413-20.
142. Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 2003;63:3069-72.
143. El Touny LH, Banerjee PP. Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells. Biochem Biophys Res Commun 2007;361:169-75.
144. Lin RK, Hsu CH, Wang YC. Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. Anti-Cancer Drugs 2007;18:1157-64.
145. Gao YS, Hubbert CC, Lu J, Lee YS, Lee JY, Yao TP. Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol 2007;27:8637-47.
146. Mottet D, Bellahcene A, Pirotte S, Waltregny D, Deroanne C, Lamour V et al. Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circul Res 2007;101:1237-46.
147. Kim SH, Kim KW, Jeong JW. Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1 alpha suppression. Oncol Rep 2007;17:793-7.
148. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Nat Cancer Inst 2000;92:1210-6.
149. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. Invest New Drugs 2000;18:7-16.
150. Saitoh Y, Koizumi K, Minami T, Sekine K, Sakurai H, Saiki I. A derivative of aminopeptidase inhibitor (BE15) has a dual inhibitory effect of invasion and motility on tumor and endothelial cells. Biol Pharmac Bull 2006;29:709-12.
151. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 2007;359:716-22.
152. Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi F et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 2005;65:5864-71. (Pubitemid 40911192)
153. Giubellino A, Gao Y, Lee SM, Lee MJ, Vasselli JR, Medepalli S et al. Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res 2007;67:6012-6.
154. Schmid G, Guba M, Papyan A, Ischenko I, Bruckel M, Bruns CJ et al. FTY720 inhibits tumor growth and angiogenesis. Transplant Proc 2005;37:110-111.
155. Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 2002;62:1410-9. (Pubitemid 34407800)
156. Lee TK, Man K, Ho JW, Wang XH, Poon RTP, Xu Y et al. FTY720: A promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 2005;11:8458-66.
157. Zhou C, Ling MT, Lee TKW, Man K, Wang XH, Wong YC. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Letters 2006;233:36-47.
158. Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T. Serine Palmitoyltransferase Is the Primary Target of a Sphingosine-Like Immunosuppressant, Isp-1/Myriocin. Biochemical and Biophysical Research Communications 1995;211:396-403.
159. Kostova I. Ruthenium complexes as anticancer agents. Curr Med Chem 2006;13:1085-107.
160. Sava G, Capozzi I, Bergamo A, Gagliardi R, Cocchietto M, Masiero L et al. Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex. Int J Canc 1996;68:60-6.
161. Colucci M, Coluccia M, Montemurro P, Conese M, Nassi A, Loseto F et al. Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 Ru(Ii)-Dmso complexes in mice bearing lewis lung-carcinoma. Int J Oncol 1993;2:527-9.
162. Serli B, Zangrando E, Gianfeffara T, Yellowlees L, Alessio E. Coordination and release of NO by ruthenium-dimethylsulfoxide complexes - implications for antimetastases activity. Coord Chem Rev 2003;245:73-83.
163. Sava G, Frausin F, Cocchietto M, Vita F, Podda E, Spessotto P et al. Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A. Eur J Cancer 2004;40:1383-96. (Pubitemid 38737025)
164. Gava B, Zorzet S, Spessotto P, Cocchietto M, Sava G. Inhibition of Bl6 melanoma metastases with the ruthenium complex imidazolium trans- imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion. J Pharmacol Exper Therapeutics 2006;317:284-91.
165. Debidda M, Sanna B, Cossu A, Posadino AM, Tadolini B, Ventura C et al. NAMI-A inhibits the PMA-induced ODC gene expression in ECV304 cells: Involvement of PKC/Raf/Mek/ERK signalling pathway. Int J Oncol 2003;23:477-82.
166. Zorzet S, Bergamo A, Cocchietto M, Sorc A, Gava B, Alessio E et al. Lack of in vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of Matrigel invasion, may predict in vivo-selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther 2000;295:927-33
167. Sanna B, Debidda M, Pintus G, Tadolini B, Posadino AM, Bennardini F et al. The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide- tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-artivated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch Biochem Biophys 2002;403:209-18.
168. Vacca A, Bruno M, Boccarelli A, Coluccia M, Ribatti D, Bergamo A et al. Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. British Journal of Cancer 2002;86:993-8.
169. Magnarin M, Bergamo A, Carotenuto ME, Zorzet S, Sava G. Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A. Anticancer Research 2000;20:2939-44.
170. Casarsa C, Mischis MT, Sava G. TGF beta(1) regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours. Journal of Inorganic Biochemistry 2004;98:1648-54. (Pubitemid 39349191)
171. Sava G, Capozzi I, Clerici K, Gagliardi G, Alessio E, Mestroni G. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Experim Metastasis 1998;16:371-9.
172. Sava G, Zorzet S, Turrin C, Vita F, Soranzo M, Zabucchi G et al. Dual action of NAMI-A in inhibition of solid tumor metastasis: Selective targeting of metastatic cells and binding to collagen. Clin Cancer Res 2003;9:1898-905.
173. Bergamo A, Cocchietto M, Capozzi I, Mestroni G, Alessio E, Sava G. Treatment of residual metastases with Na[trans-RuC14(DMSO)Im] and ruthenium uptake by tumor cells. Anti-Cancer Drugs 1996;7:697-702. (Pubitemid 26348849)
174. Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JHM. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole- tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res 2004;10:3717-27.
175. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nature Rev Cancer 2002;2:683-93.